PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31950222-1	2020	The current study was designed to evaluate potential enhancement of the anticancer activity of imatinib mesylate (IM) with dipyridamole (DIP) and to investigate the underlying mechanisms of the combined therapy (IM/DIP) to reduce hepatotoxicity of IM in solid Ehrlich carcinoma (SEC)-bearing mice.	imatinib	95-112	protein inhibitor of activated STAT 2	Mus musculus	137-140	
31950222-13	2020	DIP as an adjuvant therapy potentiated the cytotoxic effect of IM, ameliorated its hepatic toxicity, and showed synergistic effect with IM in vitro cell lines.	imatinib	63-65	protein inhibitor of activated STAT 2	Mus musculus	0-3	
31950222-13	2020	DIP as an adjuvant therapy potentiated the cytotoxic effect of IM, ameliorated its hepatic toxicity, and showed synergistic effect with IM in vitro cell lines.	imatinib	136-138	protein inhibitor of activated STAT 2	Mus musculus	0-3	
31950222-14	2020	Furthermore, the resistance against IM therapy may be overcome by the use of DIP independent on mdr-1 gene expression.	imatinib	36-38	protein inhibitor of activated STAT 2	Mus musculus	77-80